Home  >  TopNews
Clinical Trials + Font Resize -

Eli Lilly begins dosing of patients in feasibility study to evaluate functionality & safety of AID system

Indianapolis
Thursday, December 7, 2017, 12:00 Hrs  [IST]

Eli Lilly and Company has started dosing the first patient with type 1 diabetes in a feasibility study to evaluate the functionality and safety of an automated insulin delivery (AID) system. The AID system is part of the Connected Diabetes Ecosystem, which is being designed to make diabetes management easier by enabling people to use insulin more effectively.

The AID system is a hybrid closed-loop platform that uses connected devices - an insulin pump with a dedicated controller, dosing algorithm, and continuous glucose monitor - to automate insulin dosing. These components are designed to work together to automatically adjust insulin infusion rates to maintain blood sugar levels within a specified target range.

"This trial is a significant step forward for Lilly's Connected Care program, moving the Connected Diabetes Ecosystem closer to hopefully becoming available to the millions of people with diabetes who need a simpler, more effective way to use insulin," said Marie Schiller, vice president, Connected Care and site head, Cambridge Innovation Center.

The AID system is one of two platforms in development for the Ecosystem. The other is an integrated insulin management system, which combines a connected insulin pen with glucose-sensing technologies and software applications to deliver personalized insulin dose recommendations. Both platforms within the Ecosystem are currently in development, and more clinical trials will be initiated in the coming months in both people with type 1 and type 2 diabetes who use insulin. In conjunction with a variety of partners, Lilly is working to make these platforms available to patients within two to three years, pending FDA approval.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |